
FDA approves Rasonque for advanced pancreatic cancer treatment
The story in brief
The US FDA approved daraxonrasib (Rasonque), an oral once-daily pill, for advanced pancreatic cancer unresponsive to prior treatment. It is the first therapy targeting RAS protein, a key driver of the disease. Trials showed a median survival of 13.2 months vs. 6.7 months with chemotherapy, meeting primary endpoints. However, it is not yet approved as first-line treatment, and FDA approval does not guarantee immediate availability in India.